Primary Sjögren's syndrome: Clinical phenotypes, outcome and the development of biomarkers

Autoimmunity Reviews

Volumn 15, Issue 7, 2016, Pages 695-703

  Goules, Andreas V ^a,b   Tzioufas, Athanasios G ^a  

^a UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

^b JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Biomarkers; Lymphoma; Predictors; Primary Sj gren's syndrome; Systemic manifestations

Indexed keywords

BIOLOGICAL MARKER; MOLECULAR MARKER;

AUTOIMMUNE DISEASE; B LYMPHOCYTE; DISEASE CONTROL; GENETIC MARKER; HIGH RISK PATIENT; HISTOLOGY; HUMAN; IMMUNE COMPLEX DISEASE; LYMPHOMA; MORTALITY; PHENOTYPE; PROGNOSIS; REVIEW; RISK FACTOR; SJOEGREN SYNDROME; SYSTEMIC DISEASE; CHEMISTRY; IMMUNOLOGY; TREATMENT OUTCOME;

AUTOIMMUNE DISEASES; BIOMARKERS; HUMANS; PHENOTYPE; PROGNOSIS; SJOGREN'S SYNDROME; TREATMENT OUTCOME;

EID: 84961782674     PISSN: 15689972     EISSN: 18730183     Source Type: Journal    
DOI: 10.1016/j.autrev.2016.03.004     Document Type: Review

References (111)

1. Skopouli F.N., Dafni U., Ioannidis J.P., Moutsopoulos H.M. Clinical evolution, and morbidity and mortality of primary Sjögren's syndrome. Semin Arthritis Rheum 2000, 29:296-304.
2. Dorner T., Lipsky P.E. Abnormalities of B cell phenotype, immunoglobulin gene expression and the emergence of autoimmunity in Sjögren's syndrome. Arthritis Res 2002, 4:360-371.
3. Hansen A., Lipsky P.E., Dorner T. B cells in Sjögren's syndrome: indications for disturbed selection and differentiation in ectopic lymphoid tissue. Arthritis Res Ther 2007, 9:218.
4. Hansen A., Odendahl M., Reiter K., Jacobi A.M., Feist E., Scholze J., et al. Diminished peripheral blood memory B cells and accumulation of memory B cells in the salivary glands of patients with Sjögren's syndrome. Arthritis Rheum 2002, 46:2160-2171.
5. Matsumoto I., Tsubota K., Satake Y., Kita Y., Matsumura R., Murata H., et al. Common T cell receptor clonotype in lacrimal glands and labial salivary glands from patients with Sjögren's syndrome. J Clin Invest 1996, 97:1969-1977.
6. Sumida T., Yonaha F., Maeda T., Tanabe E., Koike T., Tomioka H., et al. T cell receptor repertoire of infiltrating T cells in lips of Sjögren's syndrome patients. J Clin Invest 1992, 89:681-685.
7. Ioannidis J.P., Vassiliou V.A., Moutsopoulos H.M. Long-term risk of mortality and lymphoproliferative disease and predictive classification of primary Sjögren's syndrome. Arthritis Rheum 2002, 46:741-747.
8. Sada P.R., Isenberg D., Ciurtin C. Biologic treatment in Sjögren's syndrome. Rheumatology (Oxford) 2015, 54:219-230.
9. Seror R., Theander E., Brun J.G., Ramos-Casals M., Valim V., Dorner T., et al. Validation of EULAR primary Sjögren's syndrome disease activity (ESSDAI) and patient indexes (ESSPRI). Ann Rheum Dis 2015, 74:859-866.
10. Moutsopoulos H.M. Sjögren's syndrome: autoimmune epithelitis. Clin Immunol Immunopathol 1994, 72:162-165.
11. Abu-Helu R.F., Dimitriou I.D., Kapsogeorgou E.K., Moutsopoulos H.M., Manoussakis M.N. Induction of salivary gland epithelial cell injury in Sjögren's syndrome: in vitro assessment of T cell-derived cytokines and Fas protein expression. J Autoimmun 2001, 17:141-153.
12. Dimitriou I.D., Kapsogeorgou E.K., Moutsopoulos H.M., Manoussakis M.N. CD40 on salivary gland epithelial cells: high constitutive expression by cultured cells from Sjögren's syndrome patients indicating their intrinsic activation. Clin Exp Immunol 2002, 127:386-392.
13. Kapsogeorgou E.K., Dimitriou I.D., Abu-Helu R.F., Moutsopoulos H.M., Manoussakis M.N. Activation of epithelial and myoepithelial cells in the salivary glands of patients with Sjögren's syndrome: high expression of intercellular adhesion molecule-1 (ICAM.1) in biopsy specimens and cultured cells. Clin Exp Immunol 2001, 124:126-133.
14. Kapsogeorgou E.K., Moutsopoulos H.M., Manoussakis M.N. Functional expression of a costimulatory B7.2 (CD86) protein on human salivary gland epithelial cells that interacts with the CD28 receptor, but has reduced binding to CTLA4. J Immunol 2001, 166:3107-3113.
15. Kapsogeorgou E.K., Moutsopoulos H.M., Manoussakis M.N. A novel B7-2 (CD86) splice variant with a putative negative regulatory role. J Immunol 2008, 180:3815-3823.
16. Manoussakis M.N., Dimitriou I.D., Kapsogeorgou E.K., Xanthou G., Paikos S., Polihronis M., et al. Expression of B7 costimulatory molecules by salivary gland epithelial cells in patients with Sjögren's syndrome. Arthritis Rheum 1999, 42:229-239.
17. Ping L., Ogawa N., Sugai S. Novel role of CD40 in Fas-dependent apoptosis of cultured salivary epithelial cells from patients with Sjögren's syndrome. Arthritis Rheum 2005, 52:573-581.
18. Tsunawaki S., Nakamura S., Ohyama Y., Sasaki M., Ikebe-Hiroki A., Hiraki A., et al. Possible function of salivary gland epithelial cells as nonprofessional antigen-presenting cells in the development of Sjögren's syndrome. J Rheumatol 2002, 29:1884-1896.
19. Daridon C., Devauchelle V., Hutin P., Le Berre R., Martins-Carvalho C., Bendaoud B., et al. Aberrant expression of BAFF by B lymphocytes infiltrating the salivary glands of patients with primary Sjögren's syndrome. Arthritis Rheum 2007, 56:1134-1144.
20. Ittah M., Miceli-Richard C., Eric Gottenberg J., Lavie F., Lazure T., Ba N., et al. B cell-activating factor of the tumor necrosis factor family (BAFF) is expressed under stimulation by interferon in salivary gland epithelial cells in primary Sjögren's syndrome. Arthritis Res Ther 2006, 8:R51.
21. Sfriso P., Oliviero F., Calabrese F., Miorin M., Facco M., Contri A., et al. Epithelial CXCR3-B regulates chemokines bioavailability in normal, but not in Sjögren's syndrome, salivary glands. J Immunol 2006, 176:2581-2589.
22. Kapsogeorgou E.K., Abu-Helu R.F., Moutsopoulos H.M., Manoussakis M.N. Salivary gland epithelial cell exosomes: a source of autoantigenic ribonucleoproteins. Arthritis Rheum 2005, 52:1517-1521.
23. Voulgarelis M., Dafni U.G., Isenberg D.A., Moutsopoulos H.M. Malignant lymphoma in primary Sjögren's syndrome: a multicenter, retrospective, clinical study by the European concerted action on Sjögren's syndrome. Arthritis Rheum 1999, 42:1765-1772.
24. Triantafyllopoulou A., Tapinos N., Moutsopoulos H.M. Evidence for coxsackievirus infection in primary Sjögren's syndrome. Arthritis Rheum 2004, 50:2897-2902.
25. Kyriakidis N.C., Kapsogeorgou E.K., Gourzi V.C., Konsta O.D., Baltatzis G.E., Tzioufas A.G. Toll-like receptor 3 stimulation promotes Ro52/TRIM21 synthesis and nuclear redistribution in salivary gland epithelial cells, partially via type I interferon pathway. Clin Exp Immunol 2014, 178:548-560.
26. Bové A., Ramos-Casals M. Sjögren's syndrome Diagnosis and Therapeutics 2012, 501-514. Springer-Verlag, New York. M. Ramos-Casals, J.H. Stone, H.M. Moutsopoulos (Eds.).
27. Goules A., Masouridi S., Tzioufas A.G., Ioannidis J.P., Skopouli F.N., Moutsopoulos H.M. Clinically significant and biopsy-documented renal involvement in primary Sjögren syndrome. Medicine (Baltimore) 2000, 79:241-249.
28. Goules A.V., Tatouli I.P., Moutsopoulos H.M., Tzioufas A.G. Clinically significant renal involvement in primary Sjögren's syndrome: clinical presentation and outcome. Arthritis Rheum 2013, 65:2945-2953.
29. Alamanos Y., Tsifetaki N., Voulgari P.V., Venetsanopoulou A.I., Siozos C., Drosos A.A. Epidemiology of primary Sjögren's syndrome in north-west Greece, 1982-2003. Rheumatology (Oxford) 2006, 45:187-191.
30. Brito-Zeron P., Kostov B., Solans R., Fraile G., Suarez-Cuervo C., Casanovas A., et al. Systemic activity and mortality in primary Sjögren syndrome: predicting survival using the EULAR-SS disease activity index (ESSDAI) in 1045 patients. Ann Rheum Dis 2014, 75:348-355.
31. Brito-Zeron P., Ramos-Casals M., Bove A., Sentis J., Font J. Predicting adverse outcomes in primary Sjögren's syndrome: identification of prognostic factors. Rheumatology (Oxford) 2007, 46:1359-1362.
32. Pertovaara M., Pukkala E., Laippala P., Miettinen A., Pasternack A. A longitudinal cohort study of Finnish patients with primary Sjögren's syndrome: clinical, immunological, and epidemiological aspects. Ann Rheum Dis 2001, 60:467-472.
33. Theander E., Manthorpe R., Jacobsson L.T. Mortality and causes of death in primary Sjögren's syndrome: a prospective cohort study. Arthritis Rheum 2004, 50:1262-1269.
34. Voulgarelis M., Ziakas P.D., Papageorgiou A., Baimpa E., Tzioufas A.G., Moutsopoulos H.M. Prognosis and outcome of non-Hodgkin lymphoma in primary Sjögren syndrome. Medicine (Baltimore) 2012, 91:1-9.
35. Tsokos M., Lazarou S.A., Moutsopoulos H.M. Vasculitis in primary Sjögren's syndrome. Histologic classification and clinical presentation. Am J Clin Pathol 1987, 88:26-31.
36. Kassan S.S., Thomas T.L., Moutsopoulos H.M., Hoover R., Kimberly R.P., Budman D.R., et al. Increased risk of lymphoma in sicca syndrome. Ann Intern Med 1978, 89:888-892.
37. Zintzaras E., Voulgarelis M., Moutsopoulos H.M. The risk of lymphoma development in autoimmune diseases: a meta-analysis. Arch Intern Med 2005, 165:2337-2344.
38. Hernandez J.A., Olive A., Ribera J.M., Tena X., Cuxart A., Feliu E. Probability of the development of non-Hodgkin's lymphoma in primary Sjögren's syndrome. Scand J Rheumatol 1996, 25:396-397.
39. Kruize A.A., Hene R.J., van der Heide A., Bodeutsch C., de Wilde P.C., van Bijsterveld O.P., et al. Long-term followup of patients with Sjögren's syndrome. Arthritis Rheum 1996, 39:297-303.
40. Lazarus M.N., Robinson D., Mak V., Moller H., Isenberg D.A. Incidence of cancer in a cohort of patients with primary Sjögren's syndrome. Rheumatology (Oxford) 2006, 45:1012-1015.
41. Martens P.B., Pillemer S.R., Jacobsson L.T., O'Fallon W.M., Matteson E.L. Survivorship in a population based cohort of patients with Sjögren's syndrome, 1976-1992. J Rheumatol 1999, 26:1296-1300.
42. Pavlidis N.A., Drosos A.A., Papadimitriou C., Talal N., Moutsopoulos H.M. Lymphoma in Sjögren's syndrome. Med Pediatr Oncol 1992, 20:279-283.
43. Sutcliffe N., Inanc M., Speight P., Isenberg D. Predictors of lymphoma development in primary Sjögren's syndrome. Semin Arthritis Rheum 1998, 28:80-87.
44. Valesini G., Priori R., Bavoillot D., Osborn J., Danieli M.G., Del Papa N., et al. Differential risk of non-Hodgkin's lymphoma in Italian patients with primary Sjögren's syndrome. J Rheumatol 1997, 24:2376-2380.
45. Zufferey P., Meyer O.C., Grossin M., Kahn M.F. Primary Sjögren's syndrome (SS) and malignant lymphoma. A retrospective cohort study of 55 patients with SS. Scand J Rheumatol 1995, 24:342-345.
46. Papageorgiou A., Ziogas D.C., Mavragani C.P., Zintzaras E., Tzioufas A.G., Moutsopoulos H.M., et al. Predicting the outcome of Sjögren's syndrome-associated non-Hodgkin's lymphoma patients. PLoS One 2015, 10.
47. Nishishinya M.B., Pereda C.A., Munoz-Fernandez S., Pego-Reigosa J.M., Rua-Figueroa I., Andreu J.L., et al. Identification of lymphoma predictors in patients with primary Sjögren's syndrome: a systematic literature review and meta-analysis. Rheumatol Int 2015, 35:17-26.
48. Kauppi M., Pukkala E., Isomaki H. Elevated incidence of hematologic malignancies in patients with Sjögren's syndrome compared with patients with rheumatoid arthritis (Finland). Cancer Causes Control 1997, 8:201-204.
49. Pariente D., Anaya J.M., Combe B., Jorgensen C., Emberger J.M., Rossi J.F., et al. Non-Hodgkin's lymphoma associated with primary Sjögren's syndrome. Eur J Med 1992, 1:337-342.
50. Tzioufas A.G., Manoussakis M.N., Costello R., Silis M., Papadopoulos N.M., Moutsopoulos H.M. Cryoglobulinemia in autoimmune rheumatic diseases. Evidence of circulating monoclonal cryoglobulins in patients with primary Sjögren's syndrome. Arthritis Rheum 1986, 29:1098-1104.
51. Tzioufas A.G., Boumba D.S., Skopouli F.N., Moutsopoulos H.M. Mixed monoclonal cryoglobulinemia and monoclonal rheumatoid factor cross-reactive idiotypes as predictive factors for the development of lymphoma in primary Sjögren's syndrome. Arthritis Rheum 1996, 39:767-772.
52. Gottenberg J.E., Seror R., Miceli-Richard C., Benessiano J., Devauchelle-Pensec V., Dieude P., et al. Serum levels of beta2-microglobulin and free light chains of immunoglobulins are associated with systemic disease activity in primary Sjögren's syndrome. Data at enrollment in the prospective ASSESS cohort. PLoS One 2013, 8.
53. Quartuccio L., Isola M., Baldini C., Priori R., Bartoloni Bocci E., Carubbi F., et al. Biomarkers of lymphoma in Sjögren's syndrome and evaluation of the lymphoma risk in prelymphomatous conditions: results of a multicenter study. J Autoimmun 2013, 51:75-80.
54. Risselada A.P., Kruize A.A., Bijlsma J.W. Clinical features distinguishing lymphoma development in primary Sjögren's syndrome-a retrospective cohort study. Semin Arthritis Rheum 2013, 43:171-177.
55. Baimpa E., Dahabreh I.J., Voulgarelis M., Moutsopoulos H.M. Hematologic manifestations and predictors of lymphoma development in primary Sjögren syndrome: clinical and pathophysiologic aspects. Medicine (Baltimore) 2009, 88:284-293.
56. Cohen C., Mekinian A., Uzunhan Y., Fauchais A.L., Dhote R., Pop G., et al. 18F-fluorodeoxyglucose positron emission tomography/computer tomography as an objective tool for assessing disease activity in Sjögren's syndrome. Autoimmun Rev 2013, 12:1109-1114.
57. Ramos-Casals M., Brito-Zeron P., Yague J., Akasbi M., Bautista R., Ruano M., et al. Hypocomplementaemia as an immunological marker of morbidity and mortality in patients with primary Sjögren's syndrome. Rheumatology (Oxford) 2005, 44:89-94.
58. Theander E., Henriksson G., Ljungberg O., Mandl T., Manthorpe R., Jacobsson L.T. Lymphoma and other malignancies in primary Sjögren's syndrome: a cohort study on cancer incidence and lymphoma predictors. Ann Rheum Dis 2006, 65:796-803.
59. Papageorgiou A., Voulgarelis M., Tzioufas A.G. Clinical picture, outcome and predictive factors of lymphoma in Sjögren syndrome. Autoimmun Rev 2015, 14:641-649.
60. Gerli R., Muscat C., Giansanti M., Danieli M.G., Sciuto M., Gabrielli A., et al. Quantitative assessment of salivary gland inflammatory infiltration in primary Sjögren's syndrome: its relationship to different demographic, clinical and serological features of the disorder. Br J Rheumatol 1997, 36:969-975.
61. Bournia V.K., Diamanti K.D., Vlachoyiannopoulos P.G., Moutsopoulos H.M. Anticentromere antibody positive Sjögren's Syndrome: a retrospective descriptive analysis. Arthritis Res Ther 2010, 12:R47.
62. Baer A.N., Medrano L., McAdams-DeMarco M., Gniadek T.J. Anti-centromere antibodies are associated with more severe exocrine glandular dysfunction in Sjögren's syndrome: analysis of the Sjögren's International Collaborative Clinical Alliance cohort. Arthritis Care Res (Hoboken) 2016.
63. Baldini C., Mosca M., Della Rossa A., Pepe P., Notarstefano C., Ferro F., et al. Overlap of ACA-positive systemic sclerosis and Sjögren's syndrome: a distinct clinical entity with mild organ involvement but at high risk of lymphoma. Clin Exp Rheumatol 2013, 31:272-280.
64. Ryu Y.S., Park S.H., Lee J., Kwok S.K., Ju J.H., Kim H.Y., et al. Follow-up of primary Sjögren's syndrome patients presenting positive anti-cyclic citrullinated peptides antibody. Rheumatol Int 2013, 33:1443-1446.
65. Ter Borg E.J., JC Kelder Polyarthritis in primary Sjögren's syndrome represents a distinct subset with less pronounced B cell proliferation a Dutch cohort with long-term follow-up. Clin Rheumatol 2016.
66. Carubbi F., Alunno A., Cipriani P., Bartoloni E., Baldini C., Quartuccio L., et al. A retrospective, multicenter study evaluating the prognostic value of minor salivary gland histology in a large cohort of patients with primary Sjögren's syndrome. Lupus 2015, 24:315-320.
67. Risselada A.P., Kruize A.A., Goldschmeding R., Lafeber F.P., Bijlsma J.W., van Roon J.A. The prognostic value of routinely performed minor salivary gland assessments in primary Sjögren's syndrome. Ann Rheum Dis 2014, 73:1537-1540.
68. Carubbi F., Alunno A., Cipriani P., Di Benedetto P., Ruscitti P., Berardicurti O., et al. Is minor salivary gland biopsy more than a diagnostic tool in primary Sjögren's syndrome? Association between clinical, histopathological, and molecular features: a retrospective study. Semin Arthritis Rheum 2014, 44:314-324.
69. Johnsen S.J., Berget E., Jonsson M.V., Helgeland L., Omdal R., Jonsson R. Evaluation of germinal center-like structures and B cell clonality in patients with primary Sjögren syndrome with and without lymphoma. J Rheumatol 2014, 41:2214-2222.
70. Nocturne G., Mariette X. Sjögren syndrome-associated lymphomas: an update on pathogenesis and management. Br J Haematol 2015, 168:317-327.
71. Barone F., Bombardieri M., Rosado M.M., Morgan P.R., Challacombe S.J., De Vita S., et al. CXCL13, CCL21, and CXCL12 expression in salivary glands of patients with Sjögren's syndrome and MALT lymphoma: association with reactive and malignant areas of lymphoid organization. J Immunol 2008, 180:5130-5140.
72. Bombardieri M., Barone F., Humby F., Kelly S., McGurk M., Morgan P., et al. Activation-induced cytidine deaminase expression in follicular dendritic cell networks and interfollicular large B cells supports functionality of ectopic lymphoid neogenesis in autoimmune sialoadenitis and MALT lymphoma in Sjögren's syndrome. J Immunol 2007, 179:4929-4938.
73. Christodoulou M.I., Kapsogeorgou E.K., Moutsopoulos H.M. Characteristics of the minor salivary gland infiltrates in Sjögren's syndrome. J Autoimmun 2010, 34:400-407.
74. Manoussakis M.N., Boiu S., Korkolopoulou P., Kapsogeorgou E.K., Kavantzas N., Ziakas P., et al. Rates of infiltration by macrophages and dendritic cells and expression of interleukin-18 and interleukin-12 in the chronic inflammatory lesions of Sjögren's syndrome: correlation with certain features of immune hyperactivity and factors associated with high risk of lymphoma development. Arthritis Rheum 2007, 56:3977-3988.
75. Kapsogeorgou E.K., Christodoulou M.I., Panagiotakos D.B., Paikos S., Tassidou A., Tzioufas A.G., et al. Minor salivary gland inflammatory lesions in Sjögren syndrome: do they evolve?. J Rheumatol 2013, 40:1566-1571.
76. Christodoulou M.I., Kapsogeorgou E.K., Moutsopoulos N.M., Moutsopoulos H.M. Foxp3+ T-regulatory cells in Sjögren's syndrome: correlation with the grade of the autoimmune lesion and certain adverse prognostic factors. Am J Pathol 2008, 173:1389-1396.
77. Baldini C., Gallo A., Perez P., Mosca M., Alevizos I., Bombardieri S. Saliva as an ideal milieu for emerging diagnostic approaches in primary Sjögren's syndrome. Clin Exp Rheumatol 2012, 30:785-790.
78. Ambatipudi K.S., Swatkoski S., Moresco J.J., Tu P.G., Coca A., Anolik J.H., et al. Quantitative proteomics of parotid saliva in primary Sjögren's syndrome. Proteomics 2012, 12:3113-3120.
79. Delaleu N., Mydel P., Kwee I., Brun J.G., Jonsson M.V., Jonsson R. High fidelity between saliva proteomics and the biologic state of salivary glands defines biomarker signatures for primary Sjögren's syndrome. Arthritis Rheumatol 2015, 67:1084-1095.
80. Tzioufas A.G., Kapsogeorgou E.K. Biomarkers. Saliva proteomics is a promising tool to study Sjögren syndrome. Nat Rev Rheumatol 2015, 11:202-203.
81. Hu S., Zhou M., Jiang J., Wang J., Elashoff D., Gorr S., et al. Systems biology analysis of Sjögren's syndrome and mucosa-associated lymphoid tissue lymphoma in parotid glands. Arthritis Rheum 2009, 60:81-92.
82. Flynt A.S., Lai E.C. Biological principles of microRNA-mediated regulation: shared themes amid diversity. Nat Rev Genet 2008, 9:831-842.
83. Tili E., Michaille J.J., Costinean S., Croce C.M. MicroRNAs, the immune system and rheumatic disease. Nat Clin Pract Rheumatol 2008, 4:534-541.
84. Kapsogeorgou E.K., Gourzi V.C., Manoussakis M.N., Moutsopoulos H.M., Tzioufas A.G. Cellular microRNAs (miRNAs) and Sjögren's syndrome: candidate regulators of autoimmune response and autoantigen expression. J Autoimmun 2011, 37:129-135.
85. Guarnieri D.J., DiLeone R.J. MicroRNAs: a new class of gene regulators. Ann Med 2008, 40:197-208.
86. Lodish H.F., Zhou B., Liu G., Chen C.Z. Micromanagement of the immune system by microRNAs. Nat Rev Immunol 2008, 8:120-130.
87. Michael A., Bajracharya S.D., Yuen P.S., Zhou H., Star R.A., Illei G.G., et al. Exosomes from human saliva as a source of microRNA biomarkers. Oral Dis 2010, 16:34-38.
88. Alevizos I., Alexander S., Turner R.J., Illei G.G. MicroRNA expression profiles as biomarkers of minor salivary gland inflammation and dysfunction in Sjögren's syndrome. Arthritis Rheum 2011, 63:535-544.
89. Bossen C., Schneider P. BAFF, APRIL and their receptors: structure, function and signaling. Semin Immunol 2006, 18:263-275.
90. Ferrer G., Hodgson K., Montserrat E., Moreno C. B cell activator factor and a proliferation-inducing ligand at the cross-road of chronic lymphocytic leukemia and autoimmunity. Leuk Lymphoma 2009, 50:1075-1082.
91. He B., Chadburn A., Jou E., Schattner E.J., Knowles D.M., Cerutti A. Lymphoma B cells evade apoptosis through the TNF family members BAFF/BLyS and APRIL. J Immunol 2004, 172:3268-3279.
92. Tangye S.G., Bryant V.L., Cuss A.K., Good K.L. BAFF, APRIL and human B cell disorders. Semin Immunol 2006, 18:305-317.
93. Novak A.J., Grote D.M., Ziesmer S.C., Kline M.P., Manske M.K., Slager S., et al. Elevated serum B-lymphocyte stimulator levels in patients with familial lymphoproliferative disorders. J Clin Oncol 2006, 24:983-987.
94. Novak A.J., Slager S.L., Fredericksen Z.S., Wang A.H., Manske M.M., Ziesmer S., et al. Genetic variation in B-cell-activating factor is associated with an increased risk of developing B-cell non-Hodgkin lymphoma. Cancer Res 2009, 69:4217-4224.
95. Jonsson M.V., Szodoray P., Jellestad S., Jonsson R., Skarstein K. Association between circulating levels of the novel TNF family members APRIL and BAFF and lymphoid organization in primary Sjögren's syndrome. J Clin Immunol 2005, 25:189-201.
96. Mariette X., Roux S., Zhang J., Bengoufa D., Lavie F., Zhou T., et al. The level of BLyS (BAFF) correlates with the titre of autoantibodies in human Sjögren's syndrome. Ann Rheum Dis 2003, 62:168-171.
97. Quartuccio L., Salvin S., Fabris M., Maset M., Pontarini E., Isola M., et al. BLyS upregulation in Sjögren's syndrome associated with lymphoproliferative disorders, higher ESSDAI score and B-cell clonal expansion in the salivary glands. Rheumatology (Oxford) 2013, 52:276-281.
98. Lisovsky M., Braun S.E., Ge Y., Takahira H., Lu L., Savchenko V.G., et al. Flt3-ligand production by human bone marrow stromal cells. Leukemia 1996, 10:1012-1018.
99. Tobon G.J., Saraux A., Gottenberg J.E., Quartuccio L., Fabris M., Seror R., et al. Role of fms-like tyrosine kinase 3 ligand as a potential biologic marker of lymphoma in primary Sjögren's syndrome. Arthritis Rheum 2013, 65:3218-3227.
100. Khuder S.A., Al-Hashimi I., Mutgi A.B., Altorok N. Identification of potential genomic biomarkers for Sjögren's syndrome using data pooling of gene expression microarrays. Rheumatol Int 2015, 35:829-836.
101. Rusakiewicz S., Nocturne G., Lazure T., Semeraro M., Flament C., Caillat-Zucman S., et al. NCR3/NKp30 contributes to pathogenesis in primary Sjögren's syndrome. Sci Transl Med 2013, 5.
102. Miceli-Richard C., Gestermann N., Ittah M., Comets E., Loiseau P., Puechal X., et al. The CGGGG insertion/deletion polymorphism of the IRF5 promoter is a strong risk factor for primary Sjögren's syndrome. Arthritis Rheum 2009, 60:1991-1997.
103. Korman B.D., Alba M.I., Le J.M., Alevizos I., Smith J.A., Nikolov N.P., et al. Variant form of STAT4 is associated with primary Sjögren's syndrome. Genes Immun 2008, 9:267-270.
104. Ma A., Malynn B.A. A20: linking a complex regulator of ubiquitylation to immunity and human disease. Nat Rev Immunol 2012, 12:774-785.
105. Kato M., Sanada M., Kato I., Sato Y., Takita J., Takeuchi K., et al. Frequent inactivation of A20 in B-cell lymphomas. Nature 2009, 459:712-716.
106. Nocturne G., Boudaoud S., Miceli-Richard C., Viengchareun S., Lazure T., Nititham J., et al. Germline and somatic genetic variations of TNFAIP3 in lymphoma complicating primary Sjögren's syndrome. Blood 2013, 122:4068-4076.
107. Reksten T.R., Johnsen S.J., Jonsson M.V., Omdal R., Brun J.G., Theander E., et al. Genetic associations to germinal centre formation in primary Sjögren's syndrome. Ann Rheum Dis 2014, 73:1253-1258.
108. Hildebrand J.M., Luo Z., Manske M.K., Price-Troska T., Ziesmer S.C., Lin W., et al. A BAFF-R mutation associated with non-Hodgkin lymphoma alters TRAF recruitment and reveals new insights into BAFF-R signaling. J Exp Med 2010, 207:2569-2579.
109. Nezos A., Papageorgiou A., Fragoulis G., Ioakeimidis D., Koutsilieris M., Tzioufas A.G., et al. B-cell activating factor genetic variants in lymphomagenesis associated with primary Sjögren's syndrome. J Autoimmun 2014, 51:89-98.
110. Nossent J.C., Lester S., Zahra D., Mackay C.R., Rischmueller M. Polymorphism in the 5' regulatory region of the B-lymphocyte activating factor gene is associated with the Ro/La autoantibody response and serum BAFF levels in primary Sjögren's syndrome. Rheumatology (Oxford) 2008, 47:1311-1316.
111. Papageorgiou A, Mavragani CP, Nezos A, Zintzaras E, Quartuccio L, De Vita S et al. A BAFF receptor His159Tyr mutation in Sjögren's syndrome-related lymphoproliferation. Arthritis Rheumatol 67 2732-41.